PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31366975-9	2019	However, defibrotide increased t-PA antigen levels by 31% (Quartiles: 2-49%, p = 0.026) and PAP concentrations by 13% (-4-41%, p = 0.039), while PAI-1 levels remained unaffected.	defibrotide	9-20	plasminogen activator, tissue type	Homo sapiens	31-35
31366975-10	2019	Moreover, defibrotide reduced C-reactive protein levels by 13% (0-17%, p = 0.002).	defibrotide	10-21	C-reactive protein	Homo sapiens	30-48
31366975-12	2019	In conclusion, defibrotide infusion enhanced fibrinolysis and reduced C-reactive protein levels during experimental endotoxemia.	defibrotide	15-26	C-reactive protein	Homo sapiens	70-88
28914546-6	2018	The British Committee for Standards in Haematology/British Society for Blood and Marrow Transplantation Guidelines recommend defibrotide prophylaxis in pediatric and adult HCT patients with risk factors for VOD/SOS; however, its prophylactic use in the United States is controversial.	defibrotide	125-136	xylosyltransferase 2	Homo sapiens	207-215
29579286-8	2018	Results: Mesothelioma tumor growth, measured by bioluminescence or tumor weight at termination, was markedly attenuated by heparanase gene silencing (P = .02) and by heparanase inhibitors (PG545 and defibrotide; P < .001 and P = .01, respectively).	defibrotide	199-210	heparanase	Homo sapiens	166-176
29945939-3	2018	Defibrotide, a polydisperse mixture of predominantly single-stranded polydeoxyribonucleotides, is currently the only therapy approved to treat hepatic VOD/SOS with pulmonary/renal dysfunction (ie, multiorgan dysfunction/multiorgan failure [MOD/MOF]) following HSCT in the United States and to treat severe hepatic VOD/SOS post-HSCT in the European Union.	defibrotide	0-11	lysine acetyltransferase 8	Homo sapiens	244-247
31185690-8	2019	Starting defibrotide treatment at the first signs of hepatic dysfunction in patients with particularly low BChE activity levels reduces severe liver transplant-related complications.	defibrotide	9-20	butyrylcholinesterase	Homo sapiens	107-111
27721142-5	2016	This review summarises available literature on the use of defibrotide in the management of VOD/SOS.	defibrotide	58-69	xylosyltransferase 2	Homo sapiens	95-98
29304536-0	2018	Defibrotide Stimulates Angiogenesis and Protects Endothelial Cells from Calcineurin Inhibitor-Induced Apoptosis via Upregulation of AKT/Bcl-xL.	defibrotide	0-11	calcineurin binding protein 1	Homo sapiens	72-93
29304536-0	2018	Defibrotide Stimulates Angiogenesis and Protects Endothelial Cells from Calcineurin Inhibitor-Induced Apoptosis via Upregulation of AKT/Bcl-xL.	defibrotide	0-11	AKT serine/threonine kinase 1	Homo sapiens	132-135
29304536-0	2018	Defibrotide Stimulates Angiogenesis and Protects Endothelial Cells from Calcineurin Inhibitor-Induced Apoptosis via Upregulation of AKT/Bcl-xL.	defibrotide	0-11	BCL2 like 1	Homo sapiens	136-142
18988876-0	2008	SOS! Defibrotide to the rescue.	defibrotide	5-16	xylosyltransferase 2	Homo sapiens	0-4
19809307-4	2009	In corollary laboratory studies, defibrotide has been shown to decrease plasminogen activator inhibitor-1, increase tissue plasminogen activator levels, and increase overall plasma fibrinolytic activity in patients.	defibrotide	33-44	serpin family E member 1	Homo sapiens	72-105
19809307-7	2009	Similar concentration-dependent effects of defibrotide were observed when plasmin was generated by tissue plasminogen activator or urokinase activation of plasminogen.	defibrotide	43-54	plasminogen	Homo sapiens	74-81
19809307-9	2009	Defibrotide was also able to enhance the activity of plasmin in degrading fibrin clot formed from fibrinogen, plasminogen, and thrombin.	defibrotide	0-11	plasminogen	Homo sapiens	53-60
19809307-9	2009	Defibrotide was also able to enhance the activity of plasmin in degrading fibrin clot formed from fibrinogen, plasminogen, and thrombin.	defibrotide	0-11	coagulation factor II, thrombin	Homo sapiens	127-135
23375586-4	2013	The obtained product shared similar chemical and biological properties with defibrotide produced by Gentium SpA, Italy.	defibrotide	76-87	surfactant protein A2	Homo sapiens	108-111
11441984-0	2001	Tissue factor pathway inhibitor release induced by defibrotide and heparins.	defibrotide	51-62	tissue factor pathway inhibitor	Homo sapiens	0-31
19325843-6	2008	Defibrotide, a single stranded polydeoxyribonucleotide with antithrombotic effect is also a potent CatG inhibitor.	defibrotide	0-11	cathepsin G	Homo sapiens	99-103
19325843-8	2008	A Selex protocol was applied to identify the single-stranded DNA sequences exhibiting the highest affinity for CatG, the diversity of a combinatorial pool of oligodeoxyribonucleotides being a good representation of the complexity found in defibrotide.	defibrotide	239-250	cathepsin G	Homo sapiens	111-115
18853660-19	2008	The used AD (Defibrotide, Ticlide) resulted in activation of the plasma fibrynolytic system as expressed by a shortening of the ECLT, lowering of fibrinogen level and increasing FDP.	defibrotide	13-24	fibrinogen beta chain	Homo sapiens	146-156
12414641-6	2002	As compared with rhG-CSF alone, administration of Defibrotide plus rhG-CSF resulted in a significant increase (P < or = 0.001) of the frequency of circulating long-term culture-initiating cells.	defibrotide	50-61	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	21-24
12423425-9	2002	Defibrotide treatment resulted in a significant inhibition of postreperfusion superoxide generation, lipid peroxidation, serum ALT activity, serum LDH activity, MPO activity, serum nitrite/nitrate level, leukocyte adherence to SMA, and Kupffer cell mobilization, indicating a significant attenuation of hepatic dysfunction.	defibrotide	0-11	myeloperoxidase	Rattus norvegicus	161-164
11441984-1	2001	We evaluated the release of tissue factor pathway inhibitor (TFPI) induced by defibrotide (DF), a single-stranded, negatively charged polydeoxyribonucleotide extracted from mammalian organ.	defibrotide	78-89	tissue factor pathway inhibitor	Homo sapiens	28-59
11441984-1	2001	We evaluated the release of tissue factor pathway inhibitor (TFPI) induced by defibrotide (DF), a single-stranded, negatively charged polydeoxyribonucleotide extracted from mammalian organ.	defibrotide	78-89	tissue factor pathway inhibitor	Homo sapiens	61-65
8914216-10	1996	The contractile action of serotonin, endothelin-I, serum and PRP/AA were inhibited by pretreatment of the animal with defibrotide.	defibrotide	118-129	prion protein	Canis lupus familiaris	61-64
9789870-6	1998	Defibrotide also significantly decreased PMN accumulation in the ischemic myocardium as evidenced by an attenuation in myeloperoxidase activity (p < 0.001).	defibrotide	0-11	myeloperoxidase	Rattus norvegicus	119-134
9121223-8	1996	Exposure of rat mesentery to L-NAME consistently increased P-selectin surface expression (p < 0.01) on the vascular endothelium which was significantly attenuated by defibrotide (p < 0.05).	defibrotide	169-180	selectin P	Rattus norvegicus	59-69
9121223-9	1996	In vivo administration of defibrotide can reduce leukocyte rolling and adherence in the mesenteric rat microvasculature by attenuating P-selectin expression.	defibrotide	26-37	selectin P	Rattus norvegicus	135-145
11043504-18	2000	Increased catalase activities in the blood and aortic tissues and increased glutathione peroxidase activities in the blood of rabbits receiving defibrotide suggest an induction of these antioxidant enzyme activities by defibrotide.	defibrotide	219-230	catalase	Oryctolagus cuniculus	10-18
8807723-4	1996	In a second part of the study, defibrotide has been shown to inhibit dose-dependently (10-100 microns) neutrophil activation in vitro: it decreased lysosomal enzyme release and superoxide anion and chemiluminescence production induced by the oligopeptide fMLP and the ionophores A23187 and ionomycin.	defibrotide	31-42	formyl peptide receptor 1	Homo sapiens	255-259
8807723-8	1996	The study confirms some pharmacological activities of defibrotide (release of t-PA and prostacyclin in vivo), and it also suggests that the compound blocks Ca2+ entry into the cells, possibly by interfering with the adenosine receptors.	defibrotide	54-65	plasminogen activator, tissue type	Homo sapiens	78-82
8807724-1	1996	Defibrotide, a polydeoxyribonucleotide, has been found to modulate endothelial cell function, causing an increase in tissue plasminogen activator (t-PA) levels, a decrease in plasminogen activator inhibitor (PAI) levels, and an increase in prostaglandin I2 (PGI2) formation in humans.	defibrotide	0-11	plasminogen activator, tissue type	Homo sapiens	117-151
8762067-7	1996	In basal conditions, defibrotide (1000 micrograms ml-1) partially inhibited leukocyte adhesion to endothelial cells by 17.3% +/- 3.6 (P < 0.05), and after endothelial cell stimulation (TNF-alpha, 500 u ml-1) or after leukocyte stimulation (fMLP, 10(-7) M), it inhibited leukocyte adhesion by 26.5% +/- 3.4 and 32.4% +/- 1.8, respectively (P < 0.05).	defibrotide	21-32	tumor necrosis factor	Homo sapiens	188-197
8762067-7	1996	In basal conditions, defibrotide (1000 micrograms ml-1) partially inhibited leukocyte adhesion to endothelial cells by 17.3% +/- 3.6 (P < 0.05), and after endothelial cell stimulation (TNF-alpha, 500 u ml-1) or after leukocyte stimulation (fMLP, 10(-7) M), it inhibited leukocyte adhesion by 26.5% +/- 3.4 and 32.4% +/- 1.8, respectively (P < 0.05).	defibrotide	21-32	formyl peptide receptor 1	Homo sapiens	243-247
8807723-3	1996	In the present study, the bolus administration of defibrotide in humans was able to induce (100-800 mg) a dose-dependent decrease in plasminogen activator inhibitor (PAI) (from 19.4 +/- 7.11 to 7.20 +/- 6.41 AU/mL) and an increase in t-PA (from 3.70 +/- 0.96 to 4.50 +/- 1.20 IU/mL) and in the stable prostacyclin derivative 6-keto-PGF1 alpha (from 18.83 +/- 3.83 to 26.75 +/- 8.48 pg/0.1 mL) in the venous blood.	defibrotide	50-61	plasminogen activator, tissue type	Homo sapiens	234-238
8959877-6	1996	These results, confirmed in NIH/3T3-ICAM-1-transfected cells, demonstrate that defibrotide and oligotide interfere with leukocyte adhesion to endothelial cells by an LFA-1-dependent mechanism.	defibrotide	79-90	intercellular adhesion molecule 1	Homo sapiens	36-42
8959877-6	1996	These results, confirmed in NIH/3T3-ICAM-1-transfected cells, demonstrate that defibrotide and oligotide interfere with leukocyte adhesion to endothelial cells by an LFA-1-dependent mechanism.	defibrotide	79-90	integrin subunit alpha L	Homo sapiens	166-171
7692176-3	1993	Furthermore, the increase in resting CPP induced by graded doses of endothelin-1 (ET-1 0.6-160 pmol), was further augmented by blocking of prostaglandin biosynthesis with indomethacin (3 microM) and was substantially reduced when the rate of formation of PGI2 was enhanced by defibrotide (200 micrograms/ml).	defibrotide	276-287	endothelin-1	Oryctolagus cuniculus	68-80
7602491-3	1995	Simultaneous incubation with defibrotide (0.03-0.3 mg mL-1) protected endothelial cells from tumour necrosis factor-alpha-mediated cytotoxicity, and increased viability in a concentration-dependent fashion to 98% of control at 1 ng mL-1 tumour necrosis factor-alpha and to 80% of control at 10 ng mL-1 tumour necrosis factor-alpha.	defibrotide	29-40	L1 cell adhesion molecule	Mus musculus	54-58
7602491-3	1995	Simultaneous incubation with defibrotide (0.03-0.3 mg mL-1) protected endothelial cells from tumour necrosis factor-alpha-mediated cytotoxicity, and increased viability in a concentration-dependent fashion to 98% of control at 1 ng mL-1 tumour necrosis factor-alpha and to 80% of control at 10 ng mL-1 tumour necrosis factor-alpha.	defibrotide	29-40	L1 cell adhesion molecule	Mus musculus	232-236
7602491-3	1995	Simultaneous incubation with defibrotide (0.03-0.3 mg mL-1) protected endothelial cells from tumour necrosis factor-alpha-mediated cytotoxicity, and increased viability in a concentration-dependent fashion to 98% of control at 1 ng mL-1 tumour necrosis factor-alpha and to 80% of control at 10 ng mL-1 tumour necrosis factor-alpha.	defibrotide	29-40	L1 cell adhesion molecule	Mus musculus	232-236
8052971-0	1994	Defibrotide stimulates expression of thrombomodulin in human endothelial cells.	defibrotide	0-11	thrombomodulin	Homo sapiens	37-51
8306102-19	1993	Intravenous injection of human thrombin (1250 u kg-1) to mice induces death within the majority of animals which is significantly reduced by pretreatment with defibrotide (150-175 mg kg-1, i.v.).	defibrotide	159-170	coagulation factor II, thrombin	Homo sapiens	31-39
8306102-24	1993	The protective effect of defibrotide against thrombin-induced thromboembolism in the mouse is potentiated by recombinant tissue-plasminogen activator (rt-PA; 1 mg kg-1, i.v.)	defibrotide	25-36	coagulation factor II	Mus musculus	45-53
1428206-2	1992	Heparin-assisted dialysis resulted in a significant rise of VIII:C and AT III; with defibrotide, instead, there was evidence of thrombin activation (increased FPA and TAT).	defibrotide	84-95	coagulation factor II, thrombin	Homo sapiens	128-136
1331634-6	1992	Defibrotide added in vitro to cellular systems decreased the stimulated release of beta-glucuronidase from polymorphonuclear cells (PMNs), the luminol chemiluminescence induced by oxygen species generated by stimulated PMNs and the generation of O2.- from stimulated macrophages.	defibrotide	0-11	glucuronidase, beta	Mus musculus	83-101
1509406-0	1992	Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes.	defibrotide	0-11	cathepsin G	Homo sapiens	44-55
1516602-1	1992	Defibrotide, a polydeoxyribonucleotide of mammalian origin, has been shown to reduce the blood level of the plasminogen activator inhibitor, and so to increase the activity of tissue plasminogen activator without any adverse effect.	defibrotide	0-11	chromosome 20 open reading frame 181	Homo sapiens	176-204
1516602-5	1992	A significant increase in tissue plasminogen activator activity at rest and after venostasis was observed after defibrotide; tissue plasminogen activator antigen at rest and after venostasis was not affected by either treatment.	defibrotide	112-123	chromosome 20 open reading frame 181	Homo sapiens	26-54
1519236-0	1992	Acute t-PA release by defibrotide.	defibrotide	22-33	plasminogen activator, tissue type	Homo sapiens	6-10
1663194-3	1991	The rats receiving only the vehicle for defibrotide exhibited a marked increase in intestinal myeloperoxidase (MPO) activity and a significant endothelial dysfunction manifested by the loss of endothelium-dependent vasorelaxation.	defibrotide	40-51	myeloperoxidase	Rattus norvegicus	94-109
1663194-3	1991	The rats receiving only the vehicle for defibrotide exhibited a marked increase in intestinal myeloperoxidase (MPO) activity and a significant endothelial dysfunction manifested by the loss of endothelium-dependent vasorelaxation.	defibrotide	40-51	myeloperoxidase	Rattus norvegicus	111-114
2102624-1	1990	Defibrotide, a deoxypolyribonuclide, has been found to modulate endothelial cell function causing increase in t-PA and decrease in PAI levels and also increase in PGI2 production.	defibrotide	0-11	plasminogen activator, tissue type	Homo sapiens	110-114
2126384-0	1990	Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins.	defibrotide	0-11	endothelin 1	Homo sapiens	60-72
2126384-6	1990	Defibrotide (200 ug/ml), by releasing 6-keto-PGF 1 alpha, and other vasoactive prostaglandins, antagonized the contractile effect ET-1 (20 ng) in HSV.	defibrotide	0-11	endothelin 1	Homo sapiens	130-134
1811346-0	1991	Increased plasma t-PA activity and urinary PGE2 after repeated oral administration of defibrotide to the rat and the mouse.	defibrotide	86-97	plasminogen activator, tissue type	Rattus norvegicus	17-21
1948094-1	1991	Defibrotide is a polydeoxyribonucleotide drug known to modulate the endothelial cell release of t-PA, PAI, and PGI-2 and to improve blood flow and perfusion.	defibrotide	0-11	plasminogen activator, tissue type	Homo sapiens	96-100
1948094-1	1991	Defibrotide is a polydeoxyribonucleotide drug known to modulate the endothelial cell release of t-PA, PAI, and PGI-2 and to improve blood flow and perfusion.	defibrotide	0-11	serpin family B member 2	Homo sapiens	102-105
2068563-4	1991	Although a marked increase of t-PA was seen with the active treatment, PAI activity was significantly reduced by defibrotide.	defibrotide	113-124	serpin family E member 1	Homo sapiens	71-74
2102624-1	1990	Defibrotide, a deoxypolyribonuclide, has been found to modulate endothelial cell function causing increase in t-PA and decrease in PAI levels and also increase in PGI2 production.	defibrotide	0-11	serpin family B member 2	Homo sapiens	131-134
34264868-4	2021	In vitro, defibrotide counteracted endothelial cell activation and pyroptosis-mediated cell death, whether triggered by purified NETs or recombinant histone H4.	defibrotide	10-21	LOC102641229	Mus musculus	149-159
2099323-1	1990	Defibrotide (DEF), an antithrombotic drug with no anticoagulant activity, given concomitantly with heparin potentiates its effects on thrombin time and lipase-releasing activity.	defibrotide	0-11	coagulation factor II, thrombin	Homo sapiens	134-142
2099323-1	1990	Defibrotide (DEF), an antithrombotic drug with no anticoagulant activity, given concomitantly with heparin potentiates its effects on thrombin time and lipase-releasing activity.	defibrotide	13-16	coagulation factor II, thrombin	Homo sapiens	134-142
34725956-6	2022	RESULTS: At doses ranging from 1 to 10 mug ml-1 , defibrotide significantly suppressed NET formation from control neutrophils stimulated with IgG isolated from APS patients.	defibrotide	50-61	interleukin 17F	Homo sapiens	43-47
34725956-7	2022	Defibrotide increased levels of intracellular cyclic AMP in neutrophils, and its suppressive effects on NET formation were mitigated by blocking adenosine A2A receptor or by inhibiting the cyclic AMP-dependent kinase, protein kinase A.	defibrotide	0-11	adenosine A2a receptor	Homo sapiens	145-167
34584241-5	2021	Evidence suggests that downregulating p38 mitogen-activated protein kinase (MAPK) and histone deacetylases (HDACs) is key to defibrotide"s endothelial protective effects; phosphatidylinositol 3-kinase/Akt (PI3K/AKT) potentially links defibrotide interaction with the endothelial cell membrane and downstream effects.	defibrotide	125-136	mitogen-activated protein kinase 14	Homo sapiens	38-74
34584241-5	2021	Evidence suggests that downregulating p38 mitogen-activated protein kinase (MAPK) and histone deacetylases (HDACs) is key to defibrotide"s endothelial protective effects; phosphatidylinositol 3-kinase/Akt (PI3K/AKT) potentially links defibrotide interaction with the endothelial cell membrane and downstream effects.	defibrotide	125-136	AKT serine/threonine kinase 1	Homo sapiens	201-204
34584241-5	2021	Evidence suggests that downregulating p38 mitogen-activated protein kinase (MAPK) and histone deacetylases (HDACs) is key to defibrotide"s endothelial protective effects; phosphatidylinositol 3-kinase/Akt (PI3K/AKT) potentially links defibrotide interaction with the endothelial cell membrane and downstream effects.	defibrotide	125-136	AKT serine/threonine kinase 1	Homo sapiens	211-214
34584241-5	2021	Evidence suggests that downregulating p38 mitogen-activated protein kinase (MAPK) and histone deacetylases (HDACs) is key to defibrotide"s endothelial protective effects; phosphatidylinositol 3-kinase/Akt (PI3K/AKT) potentially links defibrotide interaction with the endothelial cell membrane and downstream effects.	defibrotide	234-245	AKT serine/threonine kinase 1	Homo sapiens	201-204
34584241-5	2021	Evidence suggests that downregulating p38 mitogen-activated protein kinase (MAPK) and histone deacetylases (HDACs) is key to defibrotide"s endothelial protective effects; phosphatidylinositol 3-kinase/Akt (PI3K/AKT) potentially links defibrotide interaction with the endothelial cell membrane and downstream effects.	defibrotide	234-245	AKT serine/threonine kinase 1	Homo sapiens	211-214
34264868-6	2021	Mechanistically, defibrotide demonstrated direct and tight binding to histone H4 as detected by both electrophoretic mobility shift assay and surface plasmon resonance.	defibrotide	17-28	LOC102641229	Mus musculus	70-80
3063971-2	1988	We studied defibrotide, a new agent which enhances PGI2 release from vascular tissue, to determine its effects in a murine model of hemorrhagic shock.	defibrotide	11-22	prostaglandin I receptor (IP)	Mus musculus	51-55
3063971-9	1988	Moreover, defibrotide enhanced the recovery from norepinephrine induced vasoconstriction in rat aortic rings having an intact endothelium (p less than 0.01 from vehicle), and augmented the release of i6-keto-PGF1 alpha, the stable metabolite of PGI2, from isolated rat aortae.	defibrotide	10-21	prostaglandin I receptor (IP)	Mus musculus	245-249
33655266-4	2021	In vitro , defibrotide counteracted endothelial cell activation and cell death, whether triggered by purified NETs, COVID-19 serum containing high levels of NETs, or recombinant histone H4.	defibrotide	11-22	LOC102641229	Mus musculus	178-188
33655266-6	2021	Mechanistically, defibrotide demonstrated direct and tight binding to histone H4 as detected by both electrophoretic mobility shift assay and surface plasmon resonance.	defibrotide	17-28	LOC102641229	Mus musculus	70-80
3175328-5	1988	SAO shock rats treated with defibrotide exhibited lower plasma activities of the lysosomal protease cathepsin D (p less than 0.05 from vehicle) and myocardial depressant factor (p less than 0.02 from vehicle) as well as the plasma accumulation of free amino-nitrogen compounds (p less than 0.05 from vehicle).	defibrotide	28-39	cathepsin D	Rattus norvegicus	100-111
2459016-2	1988	Defibrotide has been found to modulate endothelial cell function causing increase in t-PA production and release with correction the defect in Cuff test in vascular disorders.	defibrotide	0-11	plasminogen activator, tissue type	Homo sapiens	85-89
3667109-7	1987	Since the stimulation of neutrophils by FMLP and A23187 depends on the increase of cytoplasmic free-calcium availability or extracellular calcium entrance respectively, whereas PMA activation is completely independent from any Ca++ change, the inhibiting effect of defibrotide could be attributed to a Ca++-involving mechanism.	defibrotide	265-276	formyl peptide receptor 1	Homo sapiens	40-44